Trials / Completed
CompletedNCT03754309
A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis
A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Kymab Limited · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to investigate if KY1005 results in improvement of eczema when given to participants with moderate to severe disease. Side effects of KY1005 will also be explored.
Detailed description
Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety and tolerability of two doses of KY1005 in adults with moderate to severe atopic dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KY1005 | A human anti-OX40 ligand monoclonal antibody |
| DRUG | Placebo | Matched placebo |
Timeline
- Start date
- 2018-12-13
- Primary completion
- 2020-05-12
- Completion
- 2020-10-08
- First posted
- 2018-11-27
- Last updated
- 2023-01-27
Locations
19 sites across 4 countries: Germany, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT03754309. Inclusion in this directory is not an endorsement.